Abstract
Apolipoprotein AV (apoAV) is a negative modulator of triglyceride metabolism, and the APOAV gene is upregulated by peroxisome proliferator-activated receptor-α (PPAR-α). Interestingly, statins have triglyceride-lowering effect and other anti-atherosclerotic effects, which may involve in the activation of PPAR-α expression. Therefore, it is plausible that statins could decrease plasma triglyceride levels by increasing APOAV expression via a PPAR-α activated pathway.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
